FR2968554B1 - Nouvelles strategies therapeutiques pour ameliorer un traitement anticancereux - Google Patents

Nouvelles strategies therapeutiques pour ameliorer un traitement anticancereux

Info

Publication number
FR2968554B1
FR2968554B1 FR1004840A FR1004840A FR2968554B1 FR 2968554 B1 FR2968554 B1 FR 2968554B1 FR 1004840 A FR1004840 A FR 1004840A FR 1004840 A FR1004840 A FR 1004840A FR 2968554 B1 FR2968554 B1 FR 2968554B1
Authority
FR
France
Prior art keywords
new therapeutic
therapeutic strategies
anticancer treatment
improve anticancer
improve
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1004840A
Other languages
English (en)
Other versions
FR2968554A1 (fr
Inventor
Veteau Isabelle Mus
Michel Bidet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Priority to FR1004840A priority Critical patent/FR2968554B1/fr
Priority to PCT/FR2011/052927 priority patent/WO2012080630A1/fr
Priority to US13/993,934 priority patent/US20140011277A1/en
Priority to CA2821223A priority patent/CA2821223A1/fr
Priority to JP2013543857A priority patent/JP2013545793A/ja
Priority to EP11811073.3A priority patent/EP2651427A1/fr
Publication of FR2968554A1 publication Critical patent/FR2968554A1/fr
Application granted granted Critical
Publication of FR2968554B1 publication Critical patent/FR2968554B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR1004840A 2010-12-13 2010-12-13 Nouvelles strategies therapeutiques pour ameliorer un traitement anticancereux Expired - Fee Related FR2968554B1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR1004840A FR2968554B1 (fr) 2010-12-13 2010-12-13 Nouvelles strategies therapeutiques pour ameliorer un traitement anticancereux
PCT/FR2011/052927 WO2012080630A1 (fr) 2010-12-13 2011-12-09 Nouvelles strategies therapeutiques pour ameliorer un traitement anticancereux
US13/993,934 US20140011277A1 (en) 2010-12-13 2011-12-09 Novel therapeutic strategies for improving an anticancer treatment
CA2821223A CA2821223A1 (fr) 2010-12-13 2011-12-09 Nouvelles strategies therapeutiques pour ameliorer un traitement anticancereux
JP2013543857A JP2013545793A (ja) 2010-12-13 2011-12-09 抗癌治療を改善するための新規治療手段
EP11811073.3A EP2651427A1 (fr) 2010-12-13 2011-12-09 Nouvelles strategies therapeutiques pour ameliorer un traitement anticancereux

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1004840A FR2968554B1 (fr) 2010-12-13 2010-12-13 Nouvelles strategies therapeutiques pour ameliorer un traitement anticancereux

Publications (2)

Publication Number Publication Date
FR2968554A1 FR2968554A1 (fr) 2012-06-15
FR2968554B1 true FR2968554B1 (fr) 2017-07-21

Family

ID=44211978

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1004840A Expired - Fee Related FR2968554B1 (fr) 2010-12-13 2010-12-13 Nouvelles strategies therapeutiques pour ameliorer un traitement anticancereux

Country Status (6)

Country Link
US (1) US20140011277A1 (fr)
EP (1) EP2651427A1 (fr)
JP (1) JP2013545793A (fr)
CA (1) CA2821223A1 (fr)
FR (1) FR2968554B1 (fr)
WO (1) WO2012080630A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170326076A1 (en) 2014-10-27 2017-11-16 Centre National De La Recherche Scientifique Panicein compounds, compositions and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002231620A1 (en) * 2000-11-06 2002-05-15 Bayer Aktiengesellschaft Regulation of human patched-like protein
WO2008039200A1 (fr) * 2006-09-27 2008-04-03 Irm Llc Procédés et compositions pour le traitement du lymphome et du myélome
US20100166848A1 (en) * 2007-09-11 2010-07-01 Joseph Ciccolini Liposomal formulations for treating cancer

Also Published As

Publication number Publication date
CA2821223A1 (fr) 2012-06-21
EP2651427A1 (fr) 2013-10-23
WO2012080630A1 (fr) 2012-06-21
FR2968554A1 (fr) 2012-06-15
JP2013545793A (ja) 2013-12-26
US20140011277A1 (en) 2014-01-09

Similar Documents

Publication Publication Date Title
RU2557654C3 (ru) Терапевтические агенты для снижения уровней паратиреоидного гормона
HUE053565T2 (hu) Adagolási rendek Pompe betegség kezelésére
BR112014012880A2 (pt) tratamento imunogênico do câncer
CO6801718A2 (es) Composición terapéutica para el tratamiento de glioblastoma
GB201511770D0 (en) Novel pharmaceutical formulationsand their use in the treatment of periodontal disease
DK2912186T3 (da) Behandling rettet mod blodplader
EP2861239A4 (fr) Compositions topiques pour le traitement de maladies inflammatoires chroniques de la peau
ITRM20120405A1 (it) Compounds for use in the treatment of disorders that are ameliorated by inhibition of hdac
FI20116093L (fi) Vettä käsittelevä laitos
FI20106078A0 (fi) Puukuitupitoisen jakeen käsittely
FR2962586B1 (fr) Panneau pour le traitement acoustique
FR2991161B1 (fr) Piece a main pour traitement endodontique
DK2694056T3 (da) Terapeutisk behandling
GB201107467D0 (en) Novel treatment of pain
FR2968554B1 (fr) Nouvelles strategies therapeutiques pour ameliorer un traitement anticancereux
FR2976806B1 (fr) Composition topique filmogene et son utilisation pour le traitement des mycoses
AP2014008006A0 (en) Treatment of acid mine drainage
FR2953412B1 (fr) Medicament pour le traitement des ulceres gastro-intestinaux
FR2992863B1 (fr) Composition pharmaceutique pour le traitement du cancer
FR2976493B1 (fr) Electrode combinee pour le traitement de l&#39;hyperhidrose
FR3005577B1 (fr) Traitement de l&#39;inconfort buccal
FR2989686B1 (fr) Traitement de formations souterraines par des gels
FR2985907B1 (fr) Composition pharmaceutique pour le traitement des dysfonctions erectiles
GB201204645D0 (en) Treatment of disease
FI20115180L (fi) Koostumus käytettäväksi sairauden hoidossa

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 10

ST Notification of lapse

Effective date: 20210805